Background
Methods
Study population and data sources
Study variables
SLE status
Vascular access at dialysis start
Vascular access placement in first year of dialysis
Loss of vascular access patency in first year of dialysis
Other variables
Statistical analysis
Results
Characteristics of the study population by SLE status and vascular access at dialysis start
Characteristic | Overall | Vascular Access on First Dialysis: | |||||||
---|---|---|---|---|---|---|---|---|---|
Any | Catheter only | AVF/AVG in place | AVF/AVG used | ||||||
Attributed Cause of ESRD: | |||||||||
SLE | Other | SLE | Other | SLE | Other | SLE | Other | ||
N (%) | 67,748 (100 %) | 517 (0.8 %) | 66,961 (99.2 %) | 384 (0.9 %) | 40,527 (99.1 %) | 85 (0.6 %) | 13,409 (99.4 %) | 48 (0.4 %) | 13,025 (99.6 %) |
Demographic | |||||||||
Mean (SD) age, years | 64.1 (14.9) | 40.3 (15.3)a | 64.3 (14.8)a | 39.0 (15.0)a | 64.1 (15.3)a | 41.7 (15.8)a | 63.8 (14.3)a | 48.6 (14.2)a | 65.4 (13.6)a |
Female, n (%) | 29,276 (43.4 %) | 410 (79.3 %)a | 28,866 (43.1 %)a | 315 (82.0 %)a | 17,951 (44.3 %)a | 64 (75.3 %)a | 5,675 (42.3 %)a | 31 (64.6 %)b | 7,785 (59.8 %)b |
Race/ethnicity, % | |||||||||
Non-Hispanic white | 34,731 (51.5 %) | 129 (25.0 %)a | 34,602 (51.7 %)a | 89 (23.2 %)a | 20,813 (51.4 %) a | 22 (25.9 %)a | 6,644 (49.6 %)a | 18 (37.5 %) | 7,145 (54.9 %) |
Black | 20,221 (30.0 %) | 284 (54.9 %)a | 19,937 (29.8 %)a | 221 (57.6 %)a | 11,984 (29.6 %)a | 42 (49.4 %)a | 4,108 (30.6 %)a | 21 (43.8 %) | 3,845 (29.5 %) |
Hispanic white | 8,722 (12.9 %) | 72 (13.9 %)a | 8,650 (12.9 %)a | 56 (14.6 %)a | 5,526 (13.6 %)a | 10 (11.8 %)a | 1,829 (13.6 %)a | —c | 1,295 (9.9 %) |
Other | 3,804 (5.6 %) | 32 (6.2 %)a | 3,772 (5.6 %)a | 18 (4.7 %)a | 2,204 (5.4 %)a | 11 (12.9 %)a | 828 (6.2 %)a | —c | 740 (5.7 %) |
Insurance at dialysis start, % | |||||||||
Private | 16,546 (24.5 %) | 137 (26.5 %)a | 16,409 (24.5 %)a | 93 (24.2 %)a | 9,441 (23.3 %)a | 25 (29.4 %)b | 3,387 (25.3 %)b | 19 (39.6 %) | 3,264 (25.1 %) |
Medicare/other | 27,159 (40.3 %) | 104 (20.1 %)a | 27,055 (40.4 %)a | 67 (17.5 %)a | 16,037 (39.6 %)a | 21 (24.7 %)b | 5,315 (39.6 %)b | 16 (33.3 %) | 3,581 (27.5 %) |
Medicaid | 18,183 (27.0 %) | 201 (38.9 %)a | 17.982 (26.9 %)a | 160 (41.7 %)a | 10,897 (26.9 %)a | 32 (37.7 %)b | 3,821 (28.5 %)b | —c | 5,703 (43.8 %) |
None | 5,590 (8.3 %) | 75 (14.5 %)a | 5,515 (8.2 %)a | 64 (16.7 %)a | 4,152 (10.3 %)a | —c | 886 (6.6 %)b | —c | 477 (3.7 %) |
Clinical | |||||||||
Pre-ESRD nephrology care, % | 38,937 (65.7 %) | 307 (67.0 %) | 38,630 (65.7 %) | 200 (60.2 %)b | 18,042 (52.4 %)b | 64 (81.0 %) | 9,034 (74.4 %) | 43 (91.5 %) | 11,554 (94.3 %) |
Mean (SD) BMI, kg/m2 | 29.5 (7.9) | 27.3 (7.5)a | 29.5 (7.9)a | 27.2 (7.5)a | 29.3 (8.0)a | 27.7 (6.9)a | 29.9 (7.9)a | 27.3 (8.3)b | 29.8 (7.7)b |
Congestive heart failure, % | 22,893 (33.9 %) | 85 (16.4 %)a | 22,808 (34.1 %)a | 59 (15.4 %)a | 14,292 (35.3 %)a | 18 (21.2 %)b | 4,819 (35.9 %)b | —c | 3,697 (28.4 %) |
Diabetes, % | 38,918 (57.7 %) | 62 (12.0 %)a | 38,856 (58.0 %)a | 44 (11.5 %)a | 22,940 (56.6 %)a | 12 (14.1 %)a | 8,401 (62.7 %)a | —c | 7,515 (57.7 %)a |
Peripheral vascular disease, % | 9,569 (14.2 %) | 21 (4.1 %)a | 9,548 (14.3 %)a | 16 (4.2 %)a | 5,494 (13.6 %)a | —c | 2,267 (16.9 %)b | —c | 1,787 (13.7 %)b |
Smoking, % | 4,369 (6.5 %) | 26 (5.0 %) | 4,343 (6.5 %) | 13 (3.4 %)b | 2,645 (6.5 %)b | 10 (11.8 %) | 889 (6.6 %) | —c | 810 (6.2 %) |
Transplanted within 1 year, % | 853 (1.3 %) | 13 (2.5 %)b | 840 (1.3 %)b | —c | 429 (1.1 %)b | —c | 160 (1.2 %) | —c | 252 (1.9 %) |
Recovered renal function within 1 year, % | 1048 (1.6 %) | 13 (2.5 %) | 1035 (1.6 %) | 11 (2.9 %) | 909 (2.2 %) | —c | 85 (0.6 %) | —c | 41 (0.3 %) |
Association of SLE status with vascular access outcomes
Vascular access placement within 1 year
Model | No. (%) with permanent access placed within 1 year | Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD | ||
---|---|---|---|---|
Unadjusted | Adjusted for demographics | Adjusted for demographics + clinical | ||
All events | ||||
SLE-attributed ESRD | 177 (46.1 %) | 0.74 (0.64-0.86) | 0.94 (0.81-1.09) | 1.00 (0.86-1.17) |
Other ESRD | 22,076 (54.5 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.001
|
<0.001
|
0.42
|
>0.9
|
All AVF placementsa | ||||
SLE-attributed ESRD | 137 (35.7 %) | 0.73 (0.62-0.87) | 0.93 (0.79-1.11) | 1.00 (0.84-1.18) |
Other ESRD | 17,300 (42.7 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.006
|
<0.001
|
0.43
|
>0.9
|
All AVG placementsa | ||||
SLE-attributed ESRD | 40 (10.4 %) | 0.77 (0.56-1.05) | 1.00 (0.73-1.38) | 1.06 (0.77-1.47) |
Other ESRD | 4,776 (11.8 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.41
|
0.10
|
>0.9
|
0.71
|
Model | No. (%) with permanent access placed within 1 year | Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD | ||
---|---|---|---|---|
Unadjusted | Adjusted for demographics | Adjusted for demographics + clinical | ||
Primary analysis | ||||
SLE-attributed ESRD | 177 (46.1 %) | 0.74 (0.64-0.86) | 0.94 (0.81-1.09) | 1.00 (0.86-1.17) |
Other ESRD | 22,076 (54.5 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.001
|
<0.001
|
0.42
|
>0.9
|
Excluding patients <18 years olda | ||||
SLE-attributed ESRD | 171 (46.2 %) | 0.74 (0.64-0.86) | 0.92 (0.79-1.08) | 0.98 (0.84-1.15) |
Other ESRD | 22,053 (54.6 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.001
|
<0.001
|
0.31
|
0.82
|
Only among patients with Medicare at ESRD startb | ||||
SLE-attributed ESRD | 67 (58.3 %) | 0.77 (0.60-0.99) | 0.83 (0.65-1.07) | 0.83 (0.65-1.07) |
Other ESRD | 15,635 (64.0 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.20
|
0.04
|
0.15
|
0.15
|
SLE and other GN compared to other ESRDc | ||||
SLE-attributed ESRD | 177 (46.1 %) | 0.73 (0.63-0.85) | 0.93 (0.80-1.08) | 0.97 (0.83-1.14) |
Other GN-attributed ESRD | 1,219 (48.6 %) | 0.83 (0.78-0.88) | 0.91 (0.86-0.96) | 0.94 (0.89-1.00) |
Other ESRD | 20,857 (54.9 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
<0.001
|
<0.001/<0.001
|
0.35/<0.001
|
0.74/0.06
|
Matched analysisd | ||||
SLE-attributed ESRD | 177 (46.1 %) | 0.85 (0.71-1.02) | 0.88 (0.73-1.06) | 0.93 (0.77-1.13) |
Other ESRD | 350 (51.7 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P
|
0.08
|
0.09
|
0.17
|
0.48
|
Events prior to 90 days included on day 91 | ||||
SLE-attributed ESRD | 177 (46.1 %) | 0.76 (0.65-0.88) | 0.94 (0.81-1.10) | 1.00 (0.86-1.17) |
Other ESRD | 22,076 (54.5 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.001
|
<0.001
|
0.46
|
>0.9
|
Events prior to 90 days excludede | ||||
SLE-attributed ESRD | 142 (40.7 %) | 0.93 (0.79-1.10) | 1.05 (0.89-1.25) | 1.07 (0.91-1.27) |
Other ESRD | 13,653 (42.6 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.48
|
0.41
|
0.56
|
0.42
|
Loss of vascular access patency in first year of dialysis
Model | No. (%) with access revision within 1 year | Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD | ||
---|---|---|---|---|
Unadjusted | Adjusted for demographics | Adjusted for demographics + clinical | ||
All patients | ||||
SLE-attributed ESRD | 21 (43.8 %) | 0.70 (0.45-1.09) | 0.81 (0.52-1.26) | 0.88 (0.57-1.37) |
Other ESRD | 7,169 (55.0 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.12
|
0.11
|
0.35
|
0.58
|
Among patients with AVFb | ||||
SLE-attributed ESRD | 19 (44.2 %) | 0.74 (0.46-1.17) | 0.86 (0.54-1.37) | 0.94 (0.59-1.50) |
Other ESRD | 5,735 (52.9 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.26
|
0.20
|
0.53
|
0.80
|
Among patients with AVGb | ||||
SLE-attributed ESRD | —c | 0.54 (0.13-2.15) | 0.57 (0.14-2.30) | 0.61 (0.15-2.47) |
Other ESRD | 1,434 (65.8 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.35
|
0.38
|
0.43
|
0.49
|
Model | No. (%) with access revision within 1 year | Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD | ||
---|---|---|---|---|
Unadjusted | Adjusted for demographics | Adjusted for demographics + clinical | ||
Primary analysis | ||||
SLE-attributed ESRD | 21 (43.8 %) | 0.70 (0.45-1.09) | 0.81 (0.52-1.26) | 0.88 (0.57-1.37) |
Other ESRD | 7,169 (55.0 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.12
|
0.11
|
0.35
|
0.58
|
Excluding patients <18 years oldb | ||||
SLE-attributed ESRD | 21 (43.8 %) | 0.70 (0.45-1.08) | 0.81 (0.52-1.26) | 0.88 (0.57-1.37) |
Other ESRD | 7,165 (55.1 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.12
|
0.11
|
0.35
|
0.57
|
Only among patients with Medicare at ESRD startc | ||||
SLE-attributed ESRD | ---d | 0.91 (0.55-1.52) | 0.86 (0.52-1.42) | 0.92 (0.55-1.53) |
Other ESRD | 1125 (13.0 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.76
|
0.73
|
0.55
|
0.75
|
SLE and other GN compared to other ESRDe | ||||
SLE-attributed ESRD | ---d | 0.69 (0.44-1.07) | 0.80 (0.52-1.24) | 0.87 (0.56-1.35) |
Other GN-attributed ESRD | 60 (6.9 %) | 0.79 (0.71-0.88) | 0.87 (0.78-0.96) | 0.91 (0.82-1.02) |
Other ESRD | 1433 (11.8 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
<0.001
|
0.10/<0.001
|
0.32/0.008
|
0.54/0.09
|
Matched analysisf | ||||
SLE-attributed ESRD | 21 (43.8 %) | 0.71 (0.42-1.19) | 0.70 (0.42-1.15) | 0.81 (0.47-1.40) |
Other ESRD | 89 (58.2 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.08
|
0.19
|
0.16
|
0.46
|
Events prior to 90 days included on day 91 | ||||
SLE-attributed ESRD | 21 (43.8 %) | 0.73 (0.47-1.13) | 0.81 (0.52-1.27) | 0.88 (0.57-1.37) |
Other ESRD | 7,169 (55.0 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.12
|
0.16
|
0.36
|
0.57
|
Events prior to 90 days excludedg | ||||
SLE-attributed ESRD | 13 (32.5 %) | 0.85 (0.49-1.46) | 0.76 (0.44-1.31) | 0.84 (0.48-1.45) |
Other ESRD | 3,377 (36.6 %) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
P |
0.59
|
0.56
|
0.32
|
0.52
|